Τόμος 14 (1996) – Τεύχος 3 – Άρθρο 5 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 14 (1996) – Issue 3 – Article 5 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Βα­σί­λης Κόκ­κας

Ερ­γα­στή­ριο Φαρ­μα­κο­λο­γί­ας, Ια­τρι­κό Τμή­μα, Α­ρι­στοτέ­λειο Πα­νε­πι­στή­μιο Θεσ­σα­λο­νί­κης, Θεσσαλονίκη, Ελ­λάς

Basilis Kokkas

Department of Pharmacology, Medical Faculty, Aristotle University of Thessaloniki, Greece

1. Granner D.: Pituitary and Hypothalamic Hormones. Ιn: Harper’s Biochemistry (Murray R., Granner D. et al., eds); p. 478, Prentice International Inc., Connecticut, 1990
2. Findling J., Tyrrell B.: Anterior Pituitary Gland. In: Basic and Clinical En­docrinology (Greenspan F., ed.); p.79, Pren­tice International Inc., Connecticut, 1991
3. Daniels G., Martin J.: Neuroendocrine regulation and dis­eases of the an­terior pituitary and hypothalamus. In: Harri­son’s Principles of Internal Medicine (Wilson J., Braunwald E., et al., eds); p.1655, McGraw-Hill Inc., New York, 1991
4. Breckwoldt M., Zahradnik H., Neulen J.: Classification and diagnosis of ovarian insufficiency. In: Infertility – Male and Female (Insler V., Lunenfield B., eds); p.224, Churchill-Livingston, New York, 1993
5. Wilson J.: Endocrine disorders of the breast. In: Harri­son’s Principles of In­ternal Medicine (Wilson J., Braunwald E., et al., eds); p.1795, McGraw-Hill Inc., New York, 1991
6. Laurence D., Bennet P.: Clinical Pharmacology; Churchil-Livingstone, New York, 1987
7. Melis G., Paoletti A., Mais V., Mastrapasqua N., Strigini F.: The effects of the GABAergic drug, sodium valproate on prolactin secretion in normal and prolacti­naemic subjects. J. Clin. Endocrinol. Metab. 54: 485-489 (1982)
8. Graves C.: Agents that cause contraction or relaxation of the uterus. In: Good­man and Gilman, The Pharmacological Basis of Therapeutics (Hardman J., et al, eds) p. 939, McGraw Hill, New York (1996)
9. Badawy S., Rebscher F., Kohn L., Walfe H., Oates R., Moses A.: The relation­ship between oral contraceptive use and subsequent development of hyperprolactinaemia. Fertil. Steril. 36: 464-467 (1981)
10. Aono T., Shioji T., Kinugasa T., Onish T., Kurachi K.: Clinical and en­docrinological analysis of patients with galac­torrhoea and menstrual disorders due to sulpiride or meto­clopramide. J. Clin. Endocrinol. Metab. 47: 675-680 (1976)
11. Cann P., Read N., Holdsworth C.: Galactorrhoea as side effect of domperidone. Br. Med. J. 286: 1395-1396 (1983)
12. Brown W., Laughren T.: Tolerance to the prolactin ele­vating effects of neuroleptics. Phychiat. Res. 5: 317-322 (1981)
13. Muller E., Locatelli V., Cella S., Penalva A., Noveli A., Cocchi D.: Prolactin lowering and releasing drugs. Mecha­nisms of action and therapeutic applications. Drugs 25: 399-432 (1983)
14. Krawiec J., Krugliak P., Levy J., Lamorecht S., Odes M.: Effect of oral cimetidine on plasma prolactin. Isr. J. Med. Sci. 17: 1183-1184 (1981)
15. Mendelson J., Ellingboe J., Mello N., Kuehnle J.: Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. J. Pharmacol. Exp. Ther. 220: 252-255 (1982)
16. Ehni G., Eckles N.: Interruption of pituitary stalk in pa­tients with mam­mary cancer. J. Neurosurg. 16: 628-652 (1959)
17. Durant P., Borrone C., Scarabichi S., Razzi A.: Hyper­pigmantation of breast areolae and external genitals with gy­naecomastia following griseofulvin treatment. Minerva Med. 55: 2422-2425 (1964)
18. Gerniez-Rieux C., Tacquet A., Macquet V.: Perfusions with ethionamide in the treatment of pulmonary tuberculosis. G. Ital. Chemioter. 10: 87-98 (1963)
19. Conn H.: Digitalis therapy and gynecomastia. J.A.M.A. 190: 1018-1019 (1964)
20. Rose L., Underwood R., Newmark S., Kischi E., Wil­liams G.: Pathophysiology of spirolactone induced gyneco­mastia. Ann. Intern. Med. 87: 398-403 (1977)
21. Miyatake A., Noma K., Nakao R., Morimoto Y., Yamamura Y.: Increased serum oestrone and oestradiol following spirolactone administration in hypertensive men. Clin. Endocr. 9: 523-533 (1978)
22. Moerch H., Magelund G.: Gynaecomastia and diazepam abuse. Lancet 1: 1344-­1345 (1979)
23. Steiner J., Cassar J., Mashiter K., Dawes I., Russell-Fraser T.: Effects of methyldopa on prolactin and growth hormone. Br. Med. J. 1: 1186-1188 (1976)
24. Olusi S.: Hyperprolactinaemia in patients with suspected cannabis induced gynecomastia. Br. Med. J. 280: 255-258 (1980)
25. Check J., Murdock M., Caro J., Hermel M.: Cystic gy­necomastia in a male treated with clomiphene citrate. Fertil-Steril 30: 713-715 (1978)
26. Friedman N., Plymate S.: Initial screening for carcino­genicity of commonly used drugs. J. Nat. Cancer Inst. 65: 723-733 (1980)
27. Bezuidenhont D.: Gynecomastia tydeus simetidin-tera­pie. S. Afr. Med. J. 54: 263­267 (1978)
28. Sharpe P., Hawkins B.: Efficacy and safety of cimetid­ine. Long-term treat­ment with cimetidine. In: Proc. 2nd Int. Symp. Histamine H2receptor antagonists (Burland W., Simpkins M., eds); pp. 358-366, Excerpta Medica, Amster­dam, 1977
29. Williams R.: Breast and thyroid cancer and malignant melanoma promoted by alcohol-induced pituitary secretion of prolactin, TSH and MSH. Lancet 2: 996-999 (1976)
30. Rosenberg L., Slone D., Shapiro S., Kaufman D., Helm­rich S.: Breast cancer and alcoholic beverage consumption. Lancet 1: 267-271 (1982)
31. LaVecchia C., Franceschi S., Cuzick J.: Alcohol and breast cancer. Lancet 1: 621-624 (1982)
32. Laska E., Seigel C., Meisner M., Fischer S., Wanderling J.: Matched-pairs study of reserpine use and breast cancer. Lancet 2: 296-300 (1975)
33. Asmstrong B., Skegg D., White G., Doll R.: Rauwolfia derivatives and breast cancer in hypertensive women. Lan­cet 2: 8-12 (1976)
34. Armstrong B., Skegg D., White G., Doll R.: Rawolfia derivatives and breast cancer in women. Lancet 2: 672-675 (1974)
35. Horrobin D., Chayur T., Karmali R.: Mind and cancer. Lancet 1: 675-677 (1974)
36. Boyland E.: Diazepam and tumour promotion. Lancet 1: 455-458 (1981)
37. Kaufman D., Shapiro S., Slone D., Rosenberg L., Helm­rich S., Miettinen O., Stolley P., Levey M.: The risk of breast cancer. Lancet 1: 537-539 (1982)
38. Gambrell D., Massey F., Castenada T., Boddie A.: Es­trogen therapy and breast cancer in postmenopausal women. J. Am. Geriat. Soc. 28: 251-257 (1986)
39. Stanford J., Weiss N., Voigt F.: Combined estrogen and prolactin hormone replacement therapy in relation to risk of breast cancer in middle aged women. J.A.M.A. 274: 137-142 (1995)
40. Πινακίδης Μ., Μπούτης Λ.: Καρκίνος μαστού; Univer­sity Studio Press, Θεσσαλονίκη, 1993
41. Hemminki E.: Oral contraceptives and breast cancer. Br. Med. J. 313: 63-64 (1996)
42. Παραδέλλης Α.: Κλινική Φαρμακολογία – Ειδικά θέματα. Κύκλος πρώτος. University Studio, Θεσσαλονίκη, 1990
43. Benet L., Kroetz D., Sheiner L.: Pharmacokinetics. In: Goodman and Gilman’s: The Pharmacological Basis of Therapeutics (Hardmann J, et al., eds); p.3, McGraw-Hill, New York, 1990
44. Abramowiez M.: Drugs in breast milk. Med. Letter 21: 21-24 (1979)
45. Anderson P.: Drugs and breast feeding. Drug Intell. Clin. Pharmacol. 11: 208-223 (1977)
46. Briggs G., Breeman R., Yaffe S.: Drugs in pregnancy and lactation (Brown C., ed.); Williams and Wilkings, Balti­more, 1986
47. Chaplin S., Sanders G., Smith J.: Drug excretion in hu­man breast milk. Adv. Drug React. Acute Pois. Rev. 1: 255-287 (1982)
48. Platzker A., Lew C., Stewart D.: Drug administration via breast milk. Hosp. Pract. 15: 111-122 (1980)